Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain

1. Sanchez-Luna, M.
2. Burgos-Pol, R.
3. Oyagüez, I.
4. Figueras-Aloy, J.
5. Sánchez-Solís, M.
6. Martinón-Torres, F.
7. Carbonell-Estrany, X.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S12879-017-2803-0 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus